Phase 2a Trial Launches for Humacyte’s Engineered Coronary Vessels
Why Tissue‑Engineered Vessels Could Change Cardiac Surgery
Humacyte, a biomanufacturing company, has begun a Phase 2a clinical study to test its tissue‑engineered vascular graft (CTEV) in patients scheduled for coronary artery bypass grafting. The study, approved by the FDA in July 2026, is now open for enrollment across several U. S. hospitals.
The trial will enroll patients undergoing standard bypass surgery, replacing diseased coronary arteries with the CTEV. Researchers aim to assess the graft’s safety, durability, and ability to integrate with native heart tissue. Early animal studies showed promising blood flow and low thrombosis rates, prompting the move to human trials.
How the Trial Is Structured
Current bypass grafts often use saphenous vein or internal mammary artery, which can fail or require reoperation. CTEV is grown from the patient’s own cells, potentially reducing rejection and improving long‑term patency. The graft’s design mimics natural artery structure, including elastic fibers and endothelial lining, which may enhance healing.
Dr. Elena Martinez, lead investigator, explained, „Our goal is to provide a graft that behaves like a living artery, adapting to the patient’s physiology over time.” The study will monitor patients for up to five years, recording graft patency, heart function, and any adverse events.
Is This the First Human Use of a Tissue‑Engineered Heart Graft?
Participants will receive the CTEV during their bypass procedure, with the graft implanted in place of a diseased coronary segment. Post‑operative imaging and blood tests will track integration and blood flow. The trial’s primary endpoint is graft patency at 12 months, while secondary endpoints include major adverse cardiac events and quality‑of‑life measures.
What If the Graft Fails?
The study will enroll approximately 120 patients across 10 centers. Randomization is not used; all participants receive the CTEV. However, a matched historical cohort of conventional graft recipients will provide comparative data.
Yes. While tissue‑engineered grafts have been tested in peripheral arteries, this is the first time a CTEV is used in a cardiac setting. The FDA’s acceptance of the investigational new drug application reflects confidence in the preclinical safety data.
Frequently Asked Questions
The trial’s success could pave the way for broader applications, including valve replacement and peripheral vascular disease.
Should the CTEV demonstrate unacceptable rates of thrombosis or failure, the study will halt further enrollment. The company plans to analyze failure modes and refine the manufacturing process.